Trend-Following Backtester · Guide · backtest 한국어

equity · CN

Sichuan Kelun Pharmaceutical Co., Ltd. Class A backtest

10 trend-following strategies were compared on the full daily history of Sichuan Kelun Pharmaceutical Co., Ltd. Class A. 0 beat buy-and-hold CAGR; SMA 크로스오버 ranks first by Sharpe, matching the main backtester.

Data 2010-06-03 ~ 2026-07-31daily bars 3,923 (16.2 years)Costs 0.5%Venue SZSEMonthly snapshot 2026-07-31

Results by strategy

0 of 10 beat buy and hold (CAGR 6.8%, drawdown -58.9%).

Sharpe leader (same as main): SMA 크로스오버 — CAGR 6.4%, MDD -50.1%, Sharpe 0.37, 53% exposure.

No strategy retained at least 75% of buy-and-hold CAGR while reducing drawdown by both 20% relatively and 5 percentage points absolutely.

The alternative must retain 75% of buy-and-hold CAGR, improve drawdown by at least 20% and 5 percentage points, and stay below 95% exposure; the ranking weights return retention 60% and drawdown improvement 40%.

Strategy · parametersCAGRMDDSharpeCalmarTotalTradesExposure
SMA 크로스오버
fast=35, slow=83
6.4%-50.1%0.370.132.7x5153%
Donchian 채널 돌파
entryN=25, exitN=50
6.2%-48.1%0.360.132.6x4366%
Supertrend
period=11, mult=4.9
3.9%-61.6%0.280.061.9x4360%
EMA 크로스오버
fast=44, slow=83
3.0%-48.5%0.250.061.6x3752%
ROC 모멘텀
n=96, threshold=0
2.3%-58.2%0.220.041.4x15150%
ADX / DI 방향성
period=26, threshold=39
0.9%-12.0%0.200.071.2x21%
볼린저 밴드 돌파
n=52, k=0.7
0.4%-66.0%0.150.011.1x12946%
MACD
fast=12, slow=89, signal=12
-1.1%-67.9%0.09-0.020.8x20251%
Keltner 채널 돌파
emaPeriod=57, atrPeriod=10, mult=2.7
-1.8%-57.8%0.01-0.030.7x5326%
Parabolic SAR
step=0.005, maxStep=0.3
-5.6%-83.3%-0.07-0.070.4x13852%
Buy and hold6.8%-58.9%0.370.122.9x1100%
1x 2011 2013 2015 2017 2019 2021 2023 2025 SMA 크로스오버Buy and hold
SMA 크로스오버: Solid strategy line versus dashed buy-and-hold line. Log scale.
0% -15% -29% -44% -59% 2011 2013 2015 2017 2019 2021 2023 2025 Buy and holdSMA 크로스오버
SMA 크로스오버 maximum drawdown -50.1% (2019-04-09 → 2026-05-18), prior peak not yet recovered.

Rules of the top strategy

When the short average rises above the long average, it reads that as an uptrend starting.

Method and caveats

Past performance does not guarantee future returns. Parameters were selected on the same full-history sample using sharpe over 40 trials per strategy, so results contain in-sample bias. 0.5% trading costs are included; taxes, slippage and rejected orders are not.
Re-run the same setupAll asset reports

Read next